A study to see how two different agents, Mitomycin C (commonly used) and bevacizumab (newer agent)influence the outcome of surgery for medically uncontrolled glaucoma.

A comparison of mitomycin C and subconjunctival bevacizumab in trabeculectomy for medically uncontrolled glaucoma.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/06/001836

Enrollment

Registered

2011-06-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Medically uncontrolled glaucoma

Interventions

Intervention1: Bevacizumab: 0.05 ml of reconstituted bevacizumab drug (1.25 mg) will be injected subconjunctivally adjacent to the bleb. Control Intervention1: Mitomycin C: 0.2 mg/ml for 1-2 minutes

Eligibility

Inclusion criteria

Inclusion criteria: - 18-70 years of age - Patients with primary or secondary, open or closed angle glaucoma. - Patients with intraocular pressure greater than 21 mmHg despite use of anti-glaucoma medications.

Exclusion criteria

Exclusion criteria: - Patients <18 years of age - Pregnant and lactating females. - Patients undergoing concurrent cataract surgery. - Patients with failed trabeculectomy. - Patients with active uveitis.

Design outcomes

Primary

Measure	Time frame
Intraocular pressure and bleb morphologic featuresTimepoint: Postoperative day 1, week 1, month 1 and month 3	—

Secondary

Measure	Time frame
Complications including systemic complications, number of antiglaucoma medications required post surgery and number of bleb needlings if any.Timepoint: Postoperative day 1, week 1, month 1 and month 3	—

Countries

India

Contacts

Public ContactParul Ichhpujani

Govt. Medical College and Hospital, Sector 32, Chandigarh

parul77@rediffmail.com09501071591

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026